BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 3042912)

  • 1. Pathogenetic studies of motor fluctuations in Parkinson's disease.
    Chase TN; Mouradian MM; Fabbrini G; Juncos JL
    J Neural Transm Suppl; 1988; 27():3-10. PubMed ID: 3042912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.
    Mouradian MM; Juncos JL; Fabbrini G; Chase TN
    Ann Neurol; 1987 Oct; 22(4):475-9. PubMed ID: 3435068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
    Fabbrini G; Juncos J; Mouradian MM; Serrati C; Chase TN
    Ann Neurol; 1987 Apr; 21(4):370-6. PubMed ID: 3579222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I.
    Fabbrini G; Mouradian MM; Juncos JL; Schlegel J; Mohr E; Chase TN
    Ann Neurol; 1988 Sep; 24(3):366-71. PubMed ID: 3228270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.
    Mouradian MM; Juncos JL; Fabbrini G; Schlegel J; Bartko JJ; Chase TN
    Ann Neurol; 1988 Sep; 24(3):372-8. PubMed ID: 3228271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
    Bravi D; Mouradian MM; Roberts JW; Davis TL; Sohn YH; Chase TN
    Ann Neurol; 1994 Jul; 36(1):27-31. PubMed ID: 8024257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for continuous dopaminomimetic therapy of Parkinson's disease.
    Chase TN; Baronti F; Fabbrini G; Heuser IJ; Juncos JL; Mouradian MM
    Neurology; 1989 Nov; 39(11 Suppl 2):7-10; discussion 19. PubMed ID: 2685653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentration-effect relationship of levodopa in patients with Parkinson's disease.
    Harder S; Baas H; Rietbrock S
    Clin Pharmacokinet; 1995 Oct; 29(4):243-56. PubMed ID: 8549026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.
    van Laar T
    CNS Drugs; 2003; 17(7):475-89. PubMed ID: 12751918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
    Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3-O-methyldopa and motor fluctuations in Parkinson's disease.
    Fabbrini G; Juncos JL; Mouradian MM; Serrati C; Chase TN
    Neurology; 1987 May; 37(5):856-9. PubMed ID: 3574690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications.
    Luer MS
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):169S-79S. PubMed ID: 10555945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.
    Fénelon G; Giménez-Roldán S; Montastruc JL; Bermejo F; Durif F; Bourdeix I; Péré JJ; Galiano L; Schadrack J
    J Neural Transm (Vienna); 2003 Mar; 110(3):239-51. PubMed ID: 12658373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When do levodopa motor fluctuations first appear in Parkinson's disease?
    Stocchi F; Jenner P; Obeso JA
    Eur Neurol; 2010; 63(5):257-66. PubMed ID: 20332641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
    Cedarbaum JM
    Neurol Clin; 1990 Feb; 8(1):31-49. PubMed ID: 2181267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basic mechanisms of motor fluctuations.
    Sage JI; Mark MH
    Neurology; 1994 Jul; 44(7 Suppl 6):S10-4. PubMed ID: 8047256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motor response complications and the function of striatal efferent systems.
    Chase TN; Mouradian MM; Engber TM
    Neurology; 1993 Dec; 43(12 Suppl 6):S23-7. PubMed ID: 8264907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Motor fluctuations in levodopa treatment: clinical pharmacology.
    Stocchi F; Bonamartini A; Vacca L; Ruggieri S
    Eur Neurol; 1996; 36 Suppl 1():38-42. PubMed ID: 8791020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.